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ABSTRACT 
Background: Constipation affects all age groups around the world and almost half of 
patients not satisfied with the current treatment. Grewia ferruginea is commonly growing 
plant in Ethiopia and used traditionally for treating many ailments including constipation 
while not approved scientifically yet. Therefore, the present study was intended to evaluate 
the laxative activity of 80% methanol extract of the leaves of G. ferruginea.  
Objective: To evaluate in vivo laxative activity of 80% methanol extract of the leaves of 
Grewia ferruginea Hochst. ex. A. Rich (Tiliaceae) in Swiss albino mice. 
Methods: The methanolic leaves extract of G. ferruginea were administered to the 
loperamide induced constipated mice. Group I, II, III, IV and V consist of constipated mice, 
treated for five days with vehicle, 100, 200 and 400mg/kg of crude extract and standard drug 
respectively. Another one group consists of normal mice was given vehicle for the same 
duration. After five days treatments the total number, weight of wet and dry feces as well as 
the water content of feces were calculated. The gastrointestinal motility test was done using 
charcoal meal in loperamide induced constipated mice. The gastrointestinal secreting effect 
of the crude extract was also determined in normal mice. Preliminary phytochemical 
screening was done. The result was expressed as mean±SEM. Statistical analysis was done 
using one way ANOVA followed by posthoc Tucky test and p<0.05 considered as significant. 
Results: Loperamide treated mice showed decrease frequency, wet weight and fecal moisture 
content compared to normal control. After five days treatment, with all doses of crude extract 
the weight of wet feces and percentage of fecal water content were increased significantly 
compared to constipated control. There was no significant difference in frequency of 
defecation. The gastrointestinal transit ratio and secreting effect of G. ferruginea were 
significant at 200mg/kg and 400mg/kg (p<0.01). Preliminary phytochemical screening 
showed that the crude extract contains phenols, flavonoids, steroids, saponins and tannins. 
Conclusion: The crude extract of the leaves of G. ferruginea showed hopeful laxative activity 
in mice at least in part via increasing intestinal motility and secretion.  
Key Words: Constipation, Laxative activity, Grewia ferruginea, loperamide
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1. INTRODUCTION  
1.1 Background 
Constipation is defined as hard or infrequent bowel movements, often associated with pain 
or a sensation of incomplete defecation (1). According Rome III criteria constipation is 
diagnosed if loose stools rarely present without laxative use and two or more of the following 
symptoms seen at least for three months in the previous six months. These include straining, 
lumpy or hard stool, sensation of incomplete evacuation, sensation of anorectal obstruction 
or blockage of defecation and need of manual maneuvers in 25% or more of defecation (2). 
Constipation can be classified into primary and secondary depending on the cause. The 
primary causes are intrinsic problems with colonic or ano-rectal function, whereas secondary 
types: normal-transit constipation, slow transit constipation, and disorders of rectal 
evacuation. In patients with normal-transit constipation disorder, no delayed of stool transit  
and the stool frequency is often within the normal range  during testing, but patients report 
and  experience the presence of  difficulty evacuating, passage of hard stools, or bloating and 
abdominal discomfort. Slow transit constipation (STC) is characterized by a shorter 
contractile activity in colon segments in response to feeding, as well as with the 
administration of a cholinergic agonist. In third disorder, it is an inability to evacuate 
adequately contents from the rectum even with soft stools (3, 4).  
1.2 Epidemiology and etiology of constipation 
Constipation affects all age groups and all nations around the world. The overall prevalence 
of chronic idiopathic constipation (CIC) in the world was 14 % and  higher in women (17.4 
%) (5). The prevalence of childhood constipation in the general population ranged from 0.7% 
to 29.6%. The prevalence increased to 59 % and 79 % in home setting elders, and geriatric 
hospital respectively. And also more than 50 % of long-term care residents use laxatives on 
a daily basis (6-8).  
In Ethiopia, Tikur Anbesa teaching hospital, among 235 patients with acute abdominal pain, 
56% shows symptom of constipation. Other studies in two Universities of Ethiopia, showed 
that the prevalence of constipation among chat chewers was 48.6-80% and non-chewers was 
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23.4% (9-11). Self-reported and physician visits for constipation is more prevalent in 
women, blacks, elders, poor’s and patients with less educated (12). 
The usual causes of constipation could be disease related like gastrointestinal disorders, 
endocrine and metabolic disorder and neurological disorders. Drugs which have 
anticholinergic effect, antidepressants, oral iron supplementation, aluminum containing 
drugs, clonidine, calcium antagonists, and ganglionic blockers which reduce smooth muscle 
contractility can cause constipation (13, 14).  
1.3 Pathophysiology of Constipation 
The gastrointestinal (GI) tract responds to input from the local environment of the gut, 
autonomic, central nervous system, hormones and enteric nervous system (ENS). The ENS 
controls the GI movements, secretion and local blood flow. The autonomic control of the GI 
tract is through parasympathetic and sympathetic nervous system. Stimulation of the 
parasympathetic system in the GI enhances activity of most gastrointestinal functions 
through the release of acetylcholine. On the other hand, stimulation of the sympathetic 
nervous system inhibits major activity of the GI tract through release nor-epinephrine and 
epinephrine (15). 
There are three types of reflexes takes place in GIT with ENS and autonomic nervous system 
coordination to regulate the all over processes in the GI system. The first reflexes are 
integrated entirely within the gut wall & ENS. These include reflexes that control much 
gastrointestinal secretion, peristalsis, mixing contractions and local inhibitory effects (16). 
Reflex circuits within the ENS initiates peristalsis, which is a series of reflex responses to a 
bolus in the lumen followed by consecutive contraction and relaxation of the smooth muscle 
on the oral and anal side respectively. Serotonin (5HT) release from entero-chromaffin cells 
when a food or stool bolus expands the gut wall and initiates local reflex. This facilitate 
enteric nerves to release stimulating neurotransmitters (acetylcholine) behind the bolus and 
relaxant substance (like nitric oxide) in front of the bolus. Then the bolus is forced forward 
along the gastrointestinal tract. In other words larger, coordinated contractions (known as 
high amplitude propagated contractions (HAPCs) bring stool forward in mass movements 
from the ascending colon down to the left colon (3). The second type of reflexes are from 
the gut to the prevertebral sympathetic ganglia and then back to the GIT. These reflexes 
transmit signals long distances to other areas of the GIT. These include gastrocolic reflex 
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signals from the stomach to the colon to cause evacuation, enterogastric reflexe signals from 
the colon and small intestine to stomach to inhibit stomach motility and secretion, and 
colonoileal reflex signals from the colon to ilium to inhibit emptying of ileal-contents into 
the colon. The third type of reflexes are from the gut to the spinal cord or brain stem and then 
back to GIT. These include reflexes from the stomach and duodenum to the brain stem and 
back to the stomach through vagus nerves to control gastric motor and secretory activity; and 
defecation reflexes that travel from the colon and rectum to the spinal cord and back again 
to produce the powerful colonic, rectal, and abdominal contractions required for defecation  
(16).  
Gastrointestinal epithelium also plays a major role in the control of fluid and ion balance. 
The feces are normally 75% water and 25% solid matter (3). Gut epithelia have two pathways 
for water transport: the paracellular route, and the transcellular route. The transcellular 
movement include passive diffusion, cotransport with ions and nutrients and diffusion 
through aquaporins (AQPs). AQP mediate water secretion and absorption in GI tract. 
Because of tight epithelium colonic mucosa characterized by high electrical resistance, it is 
very likely that water movement takes place mainly through AQPs. The impaired AQP 
expression may account for an imbalance of absorptive/secretive mechanisms. Vasoactive 
intestinal polypeptide (VIP), a gut hormone, enhance  intestinal water secretion by up 
regulating of AQP3 expression (17).  
The GIT not only absorbs water but ions and electrolytes also. The intestinal mucosa also 
has a high ability of sodium absorption actively, and secretion of bicarbonate ions in 
exchange of chloride ion absorption. The electrical potential gradient created by absorption 
of the sodium and chloride helps to water absorption (16). High transport of NaCl in the 
colonic epithelium is due to electro-neutral absorption by luminal Na+/H+ and Cl-/HCO3- 
exchange. The remaining absorption is via luminal epithelial sodium channel (ENaC) and 
transcellular or paracellular absorption of chloride. The Cl2/HCO3 anion exchange regulated 
by cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel (18) (see 
Figure 1).  
Atrial natriuretic peptide (ANP) found in mucosal layer of the small intestine, inhibits Na-
K-C1 co-transport across the intestinal wall and regulates water and salt balance in the 
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gastrointestinal tract (19). This complex process needs coordinated entero-endocrine and 
neuromuscular control to function properly. 
Normal defecation and maintenance of continence is a complex process requiring rectal 
filling, sensation of rectal filling, and the ability to propel the stool and relax the pelvic floor 
muscles in a coordinated fashion. During normal evacuation, stool distends the rectum, 
causes reflex relaxation of the internal anal sphincter and produces the feeling of the need to 
evacuate (3).  
The pathophysiologic mechanism of constipation divided broadly into two. The first one is 
dysmotility, which is failure of coordinated motor activity to move stool through the colon. 
It is associated with: dietary factors, medications that can alter motility; or systemic disease 
(e.g. neurologic, colonic neuromuscular diseases, decrease in the frequency of HAPCs, 
metabolic, or endocrine disorders); abnormalities of the enteric nerves (decrease volume of 
ICC). The second mechanism include disorders of the anorectum and pelvic floor, which 
result in outlet dysfunction and inability to adequately evacuate rectal contents. Others like 
water and electrolyte transporter related problems in the GIT plays a great role in the patho-
physiology of constipation (20). 
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Figure 1 Models for electrolyte transport in proximal and distal colonic epithelium and 
expression of different ions  
A) Electroneutral absorption of NaCl.  Na+ absorbed in exchange to H+ and Cl- absorbed in 
exchange to HCO3- at luminal side, basolateral Na+/k+ exchange with ATPase. K+ 
cotransport with Cl- and by k+ channel and recycle. B) Electrogenic transport in luminal side 
is by epithelial Na+ channel, Cl- by CFTR (18) 
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1.4 Management of Constipation 
1.4.1 Non-pharmacological Management 
In the management of constipation, identifying the cause and try to alleviate it. The common 
non-pharmacologic management includes dietary (fiber and adequate fluid intake), life style 
modification and surgery  for selected group of patients (21). 
1.4.2 Pharmacological Treatment 
Bulk forming laxatives 
Mild constipation can be managed with simple bulking agents alone or combining with 
others. They are natural or synthetic polysaccharides or cellulose derivatives that primarily 
exert their laxative effect by absorbing water and increasing fecal mass. Bulk forming 
laxatives include psyllium, methylcellulose and calcium polycarbophil (22). 
Osmotic laxatives 
The laxative effect has been attributed to their poor GI absorbability and hyper-osmolality in 
the gut. They draw water into the intestine, increases fecal fluidity and stimulate intestinal 
motor activity. Recent studies showed that three of thirteen aquaporin (AQP3, AQP4 & 
AQP8) expressed highly in the epithelial cells of colon. Osmotic laxative like magnesium 
sulphate (MgSO4), thought to act by increasing the AQP3 expression (23). 
Stimulant laxatives 
Stimulant laxatives possess multiple effects on intestinal function. These agents can convert 
net fluid and electrolyte absorption to net fluid secretion and accumulation. They also alter 
mucosal permeability, stimulate active anion secretion and induce intestinal motor activity 
through direct stimulation of the nerve endings in the colonic mucosa. These includes, 
medications like castor oil, dihydroxy bile acids, bisacodyl. All these medication also 
increase release of prostaglandin E2 (PGE2) into the lumen which in turn reverse net 
absorption of water and electrolyte to a profuse net secretion (24, 25). 
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Colonic Secretagogues  
Chloride transport is vital in the regulation of fluid secretion into the intestine. The activation 
of the apical chloride channels leads to secretion of chloride ions (Cl-) and increasing of 
mucosal hydration throughout the GI tract (eg. Lubiprostone). Another drug linaclotide is 
guanyl cyclase C (GC-C) receptor agonist that stimulates intestinal secretion by increasing 
the production of cGMP. This leads to activation of a cGMP-dependent protein kinase II and 
phosphorylation of the cystic fibrosis trans-membrane conductance regulator (CFTR). 
Activation of CFTR opens the chloride channel, resulting in chloride anion and fluid 
secretion into the lumen. It also enhance gastrointestinal motility in dose dependent manner 
(26). 
High bile acid absorption (Na+-dependent ileal bile acid transport) associated with 
constipation. Drugs act by partial inhibition of bile acids re-uptake in the terminal ileum, 
leads to more bile acids entrance to the colon and stimulate colonic motility. It also increased 
number of spontaneous bowel movements and improved stool consistency (27). 
Opioid antagonists  
Opioid receptors are located in the mucosa and myenteric plexus of the ileum and activation 
of the bowel µ-opioid receptors indirectly decrease the fluid secreted in the small bowel and 
increases water absorption in the colon. Opioids also contribute to decreased bowel motility 
through compromising the release of acetylcholine, which results a decrease in 
parasympathetic activity. Selective blockade of these peripheral receptors could relieve 
constipation (28).  
Serotonin (5HT4) receptor agonists  
Serotonin (5-HT4) receptor agonists enhance gastrointestinal motility in response to intra-
luminal stimuli, whereas antagonists suppress motor activity. Since there are many subtype 
of serotonin receptors 5HT4, selective agonists like prucalopride and tegaserod (partial 
agonist) are preferred to treat constipation (29). 
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1.5 Literature Review 
Around the world there are many traditional treatments for relieve of constipation. Psyllium 
Husk (Ispaghula) is one of such plant used for treating constipation. Presence of high fiber 
and mucilaginous contents helps to  increased stool water content, total stool output and 
bowel movement  frequency through 5-HT mediated receptors (30).  
Flaxseeds (Linum usitatissimum) can be used as a bulk producing laxative. These seeds are 
packed with a lot of fiber, vitamins, minerals and polyunsaturated fats such as omega 3 fatty 
acids. Flaxseeds also help in stimulating the peristaltic contractions of the gut (31). 
Cascara Sagrada  contains anthroquinones that tend to have strong stimulating or purgative 
action on colon muscles, enabling the muscles to contract forcefully and to produce the urge 
for evacuation (32). 
Laxative activity of medicinal plants could be evaluate using constipated or normal animals. 
Induction of constipation using loperamide is a common practice to study the laxative 
activity of different plant extract. A single 5mg/kg oral administration of loperamide 
decrease weight of wet feces and fecal water content. The leaf extract of Mareya micrantha 
(Benth.) showed increase fecal output in normal, loperamide induced constipated rats. It also 
shows increased GI transit ratio, water and electrolyte secretion (33). 
Administering loperamide 4mg/kg  subcutaneously twice daily for three days (34) or  3mg/kg 
orally once daily for three days (35) or 2 mg/kg twice a day for 7 days (36) and other more 
doses can effectively induced constipation. Epidemiological studies also showed that 
constipation occur in 85% of patients treated with opioids (37). 
Preliminary phyto-chemical analysis indicated that different plant species used to alleviate 
constipation contains oils, moisture, mucilage, and secondary metabolites like flavonoid, 
glycosides, alkaloids, saponins  anthraquinones, tannins and triterpenoids (38, 39). 
Chemical constituents found in some Grewia species were triterpenoids, alkaloids, sterols, 
flavones, tannins, saponins, glycosides, phenols, anthocyanins, lignans, vitamins C, lactones 
(40, 41) and others chemical components like propyl palmitate, butanoic acid , propanoic 
acid were  also found. The mucilage and aqueous extract of the G. tiliafolia bark are used as 
an antidote for opium poisoning in human adults (42, 43). 
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1.6 The Experimental Plant 
The genus Grewia (family: Tiliaceae) comprises approximately 150 species. They are small 
trees or shrubs, distributed in subtropical and tropical regions, including tropical Africa, 
Asia,  and northern Australia (42). The plant, locally known as Lenquata , is a wide spread 
shrub, growing near lakes and along rivers in Weyna Dega and Kolla between 1,300-2,700 
m. It is shrub or small tree to 7 m. The leaf and flower stalks covered with red brown hairs. 
Its’ leaves long oval to 13 cm, tip pointed or rounded, edge toothed and 3 veins from the 
base. The flowers are yellow, purple or white, solitary or in two or four, in a terminal head 
about 5 cm long, the central flowers opening first. The fruits in 4 parts, each rounded and 
fleshy about 5 mm across. Its fruit is edible, so couldn’t have toxicity on human being. Their 
stems are often tough and durable and thus have used for clubs, walking sticks and handles 
of farm implements (44, 45). 
Different family of grewia has many traditional benefit for human being. The root decoction 
of Glyphaea brevis (Spreng) Monachino used for aphrodisic, appetizer and laxative. 
Corchorus capsularis and Corchorus olitorius leaf has laxative, antihelmentic, dyspepsia and 
diuretic effect (46, 47). 
Similarly, different genus of Grewia has many medicinal applications in different culture of 
the world. Moisture, starch, fiber and nutritional values from G. tenax, G. flavescence, G. 
villosa was found (48). Grewia speciess’ also has different benefit in gastrointestinal 
disorder. The fruits of G. asiatica claimed to be beneficial for anorexia, indigestion, and 
stomatitis. The bark is used as a soap substitute (49). G. tenax for digestion, G. damine and 
G. flavescens leaves for stomach ulcer and skin disease (50), G. sclerophylla as emollient 
enema (41). G. tiliafolia has isolation of g-lactones, having hepato-protective activities. G. 
bicolor for stomach disease/worms, intestinal infection, laxative and the active compound 
extracted from root shows a serotonin-like effect on rat uterus, rat fundus and rabbit jejunum 
which was reversed by methysergide (51, 52).  
Ethnobotanical and experimental studies on G. ferruginea indicate that, it has many 
medicinal value for humans and animals such as kidney infection, intestinal parasite (51), 
worm expulsion (53), retained fetal membrane (54), constipation (55), as a soap for hair wash 
in the treatment of  dandruff (56) and anti-bacterial and anti-fungal activity (57).  
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Figure 2 Photograph of the plant Grewia ferruginea Hochst. ex. A. Rich 
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1.7 Rationale of the Study  
Up to one-fifth of the general population suffers from chronic constipation during their 
lifetime. Almost 85 % of physician visits for constipation need laxatives and more than $ 
820 million are spent per year on over the counter laxatives (58). Studies also showed that 
around 47% of patients not satisfied with their current constipation treatment and their reason 
for dissatisfaction were efficacy related (82%) like less effective, inconsistent results and 
continuous dosage. Other reasons for dissatisfaction included safety, adverse effect and costs 
(59). Medication costs (45%), hospital care costs for the disease and related co-morbidities 
were the high cost expense in patients with newly diagnosed chronic constipation (60) . 
Use of traditional and complementary and alternative medicine (CAM) is common around 
the globe. According to WHO estimates about 80% of Africa and, 40% of China population 
depends on traditional plant for their primary health care needs because of acceptance among 
many populations, high accessibility and affordability of medicinal plants for the poorest 
patients (61). Since high percentages of useful drugs were obtained from traditionally used 
plants by scientific investigation, it is a good approach for discovering other useful drugs 
from plants. For example danthron (1,8 dihydroxy, anthraquinone), cassia species, 
sennosides A&B, castor oil, found from plants (62). The use of traditional medicine in 
Ethiopia also accounted several thousands of years. A study showed that approximately 80% 
of human population and 90% of livestock in Ethiopia depend on traditional medicines to 
treat different diseases including constipation. Development and incorporation of traditional 
medicine with the modern system have great role in the expansion of the health care coverage 
(63). 
G. ferruginea  is one of such plant which is used traditionally for treating constipation even 
not proven scientifically yet (55). Therefore, this study validates the supposed laxative 
activity of the crude extract of G. ferruginea. The finding of this study could provide an 
opening basis about the nature of phytochemical constituents responsible for the laxative 
activity of the plant and the possible mechanisms of action. These findings also give 
scientific evidence to the traditional healers, for the use of G. ferruginea for constipation and 
point out the need for additional research in this area. 
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2. OBJECTIVE 
2.1 General Objective 
 To evaluate laxative activity of 80% methanol extract of the leaves of Grewia 
ferruginea Hochst. ex. A. Rich in Swiss albino mice 
2.2 Specific Objectives 
 To evaluate acute oral toxicity of 80% methanol extract of the leaves of G. ferruginea 
in mice. 
 To evaluate laxative effect of 80% methanol extract of the leaves of G. ferruginea in 
loperamide induced constipated mice 
 To evaluate gastrointestinal motility effect of 80% methanol extract of the leaves of 
G. ferruginea in loperamide induced constipated mice  
 To determine the gastrointestinal secreting effect of 80% methanol extract of the 
leaves of G. ferruginea in normal mice 
 To carry out preliminary phytochemical screening of 80% methanol extract of the 
leaves of G. ferruginea 
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3. MATERIALS AND METHODS  
3.1 Drugs and Chemicals 
Methanol absolute (L138101407, Loba Chemie, India), Distlled water, Loperamide HCl 
(FLL501A, Macleods pharmaceuticals LTD, India), castor oil (OA160, Amman 
pharmaceutical industries CO., Jordan), Bisacodyl 5mg (70613, Remedica-Cyprus), Tween 
80 (44759 LR, Blulux laboratories (P) Ltd, India), Glacial acetic acid, Mayer's reagent (Fine 
chemicals, A.A, Ethiopia), Ammonia, Ferric chloride (Fisher Scientific CO, USA), lead 
acetate), sulfuric acid, Benzene (44759 LR, Blulux laboratories Ltd, India), was used in this 
study. 
3.2 Plant Materials 
The leaves of G. ferruginea was collected from North Gondar around Maraki area in 
December 2016. Identification and authentication of the plant specimen was done by a 
Botanist, and voucher number MY001 was deposited in Gondar University herbarium for 
future references. 
3.3 Experimental Animals 
Swiss albino mice of weight 20-30g of either sex was obtained from the animal house unit 
of Ethiopian Health and Nutrition Research Institute (EHNRI), Addis Ababa, Ethiopia. The 
mice were housed in plastic cages under standard environmental conditions with a 12 h light 
and dark cycle. The animals provided the standard food and water ad libitum. They were 
acclimatized for a period of 7 days before beginning of the experiment.  
3.4 Plant Preparation and Extraction 
The plant leaves were rinsed and cleaned to remove dust, and dried at room temperature 
under shade area. The dried pieces were powdered coarsely using mortar and pestle. A total 
of 900g of coarse powder was macerated in 80% methanol for the extraction. One hundred 
gram of coarse powder was macerated with 500ml of 80% methanol. It was shacked 
occasionally and kept for 72h at room temperature. The extract was filtered through filter 
paper grade 3 and the marc was re-macerated with the same volume of solvent two times. 
The methanol was then removed from the extract by using a rotatory evaporator (RE 200, 
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Germany) and the aqueous part were dried using the freeze drier (Ningbo Scieentz 
Biotechnology, China). 
The resulting dried extract was weighed and calculated for percentage yield. The dried plant 
extract was reconstituted with 2% tween 80 suspending agent for oral administration. 
3.5 Preliminary phytochemical Screening Test 
The crude extract of the leaves of G. ferruginea was tested using standard procedures for the 
presence of secondary metabolites. Color changes and precipitation formation of the crude 
extract was used as an assay methods (64-67) see9. ANNEX.  
3.6 Acute Oral Toxicity Test 
An acute oral toxicity test was conducted according to OECD 425 guideline (68). Five 
healthy, non-pregnant female albino mice were chosen. Food but not water was withheld 3 
hours prior and 2 hours after the test extract administration. The crude extract was 
administered at a dose of 2000mg/kg for the first animal and observed for 24 hours with 
special attention during the first 4 hours, at least once in 30 minutes. The same dose was 
given consecutively up to fifth animal. All mice were followed up for 14 days for signs of 
toxicity and death. 
3.7 Induction of constipation and Screening  
Loperamide hydrochloride was administered orally 5 mg/kg in 2% tween 80 daily for 6 days. 
The normal control group treated with 2% tween 80 (v/v), 10ml/kg. All animals were 
accessed food and water ad libitum (69, 70).  
After six day induction of constipation, twenty five loperamide treated animals were divided 
randomly into five groups (n=5). Animals were fasted overnight before sixth dose 
administration to avoid feeding contributions. Following sixth dose administration the stool 
was collected from individual mouse in separate cages over twelve hours. Each loperamide 
treated group  mean fecal pellet numbers, weight of wet, weight of dry feces and stool water 
content were compared against normal control group (71). Dunnet post hoc analysis was 
used to observe significant induction of constipation at p<0.05. Decreased frequency, weight 
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of wet feces and fecal water content were used as screening parameters (35, 72). The same 
procedure was used to screen for GI motility test. 
3.8 Dose selection 
The methanol extract of G. ferruginea doses were selected based on the acute toxicity study. 
The middle dose (200mg/kg) was one-tenth of the limit dose. The highest and lowest dose 
was calculated as twice and half of the middle dose which was 400mg/kg and 100mg/kg 
respectively (73).  
3.9 Laxative activity test in loperamide induced mice 
In this model, initially loperamide induced male mice were divided into five groups of each 
five mice. The sixth group was used as normal control. All constipated and normal control 
mice were treated daily for 5 days as follows. 
Group 1 (normal control) treated with 10ml/kg, 2% tween 80 
Group 2 (constipated control) treated with 10ml/kg, 2% tween 80  
Group 3, 4 and 5 (constipated) treated with 100, 200 and 400mg/kg of crude extract 
respectively. 
Group 6 (constipated) treated with bisacodyl 0.25mg/kg (positive control). 
After the mice were treated for four consecutive days, they were allowed to fast overnight 
before the fifth dose was administered. After fifth dose administration they were kept in 
separate cages with non-absorbable paper. Fresh stool pellets from individual mice were 
collected in a 2 hour interval over a 12 hour period and counted the number of pellets/number 
of feces and measured weight of wet feces. The fecal matter was dried for 24 hours at room 
temperature and weighed to determine dry fecal weight. Then the fecal water content (%) 
was calculated from the difference between the weight of wet feces and weight of dry feces 
by the following formula (70). 
Fecal water content (%) = 
Fecal weight before dried − Fecal weight after dried
Fecal weight before dried
∗ 100 
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3.10 Gastrointestinal motility test in loperamide induced constipated mice 
To investigate the GI motility effect of the crude extract, loperamide induced male mice were 
divided and treated as described in section 3.9 above. Animals were treated daily for five 
days. Before the fifth dose was administered, they were fasted for 12 hours with free access 
to water. After 40 minutes of fifth dose administration, all animals were given 0.3 ml/mouse 
of freshly prepared (5% aqueous suspension) charcoal meal orally. After 30 minutes of 
charcoal meal administration, the animals were sacrificed and the small intestine was 
dissected out from the pylorus to ilo-cecum region. Finally, the ratio of distance travelled by 
the charcoal meal to the length of small intestine was calculated as follows (74).  
GI Transit ratio (%) = 
 Distance traveled by charcoal meal
Total length of small intestine
∗100 
3.11 Gastrointestinal Secretion test in normal mice 
The method of Robert et al  and Meite et al (33, 75) was used with slight modification. 
Twenty five female albino mice were grouped into five (n=5) and fasted over 18hrs. The first 
group (negative control) treated with 2% tween 80, 10ml/kg. Group 2, 3, 4 (test groups) were 
given 100,200,400 mg/kg crude extract, respectively, and the last group (positive control) 
was given castor oil 0.5ml/mouse. After one hour administration, all the animals were 
sacrificed (76). The small intestine was tied at both ends and cut out from the pylorus to the 
ileo-cecal junction. The weight of small intestine was measured before and after milking its 
content. The weight difference was calculated and compared with the negative control.  
3.12 Statistical Analysis 
The result was expressed in mean±standard error of mean (S.E.M). Statistical analysis was 
done using one way ANOVA followed by post-hoc Tukey multiple comparison test to find 
out a significant difference between the control group and test groups using SPSS version 
20. The value of P<0.05 was considered statistically significant.  
3.13 Ethical Clearance 
Care and handling of animals were in accordance with internationally accepted guidelines 
for the use of animals (77). All the experimental procedures were approved by the University 
of Gondar Research and Ethical Review Board and ethical clearance was obtained.  
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4. RESULT 
4.1 Plant Extract 
From the total of 900grams coarse powder of G. ferruginea leaves 114.56g (12.73%) dried 
extract was found. 
4.2 Phytochemical screening tests 
The preliminary phytochemical screening test showed the presence of phenols, flavonoids, 
steroids, saponins and tannins (Table 1). 
Table 1  Preliminary phytochemical screening test results of hydromethanolic extract of G. 
ferruginea   
Phytochemicals Types of Test Result 
Alkaloids Mayer’s test - 
Glycosides  Keller-kilani test - 
Phenols Ferric chloride test + 
Flavonoids Lead acetate test + 
Steroids Salkowski test + 
Terpenoids Salkowski test - 
Anthroquinones  Borntrager’s test - 
Saponins Faom test + 
Tannins Ferric chloride test + 
“+”, presence “-“, absence 
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4.3 Acute oral toxicity test 
The animals given limit dose 2000mg/kg of methanol 80% leaf extract of G. ferruginea 
showed no sign of toxicity except hunched posture, erect furs and slight diarrhea during the 
first four hours. No animals were died in the 2 week follow up period.  So, LD50 of the 
extract is greater than 2000mg/kg. 
4.4 Laxative activity evaluations 
4.4.1 Laxative effect of crude extract in loperamide induced constipated mice  
Frequency and weight of wet feces decreased in the constipated control group compared to 
a normal control group (p<0.05). It also showed decreases in the mean percentage of fecal 
moisture content relative to constipated control (p<0.01) as shown in Table 2 below. 
Treatment with crude extract of G. ferruginea increased weight of wet feces and percentage 
of moisture content relative to constipated control significantly  at 100mg/kg (p<0.05), 200 
and 400mg/kg (p<0.01) doses. The standard drug (bisacodyl) also significantly increased 
frequency, weight of wet and fecal water content compared to constipated control (p<0.001). 
There was no significant difference in frequency of defecation between crude extract 
treatment group and constipated group. In the present study, there was no also any significant 
difference between different doses of crude extract.  
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Table 2 Laxative effect of crude hydromethanolic extract of leaves of G. ferruginea in 
loperamide induced constipated mice 
Group Dose Number of 
pellets in 12 
hours 
Weight of 
wet feces 
Weight of 
dry feces 
Fecal water 
content (%) 
Constipated 
control (2% 
tween 80) 
10ml/kg 3.80±0.80 0.76±0.04 0.44±0.03 41.71±1.57 
Normal control 
(2% tween 80)  
10ml/kg 9.40±1.29 a1 0.97±0.12 a1 0.41±0.02 58.18±1.34 a2 
 
Constipated + 
crude extract 
100mg/kg 7.80±0.86 1.02±0.02 a2 0.48±0.03 52.84±3.83a1 
200mg/kg 7.60±1.99 1.03±0.01 a2 0.46±0.02 55.20±2.02 a2 
400mg/kg 7.00±1.18 0.99±0.04 a2 0.45±0.02 54.25±2.5 a2 
Positive control 
(Bisacodyl) 
 0.25mg/kg 9.60±0.68a1 1.09±0.09 a3 0.37±0.04 66.10±2.76 
a3b1 
Result expressed as mean±SEM, (n=5) 1P<0.05, 2p<0.01, 3p<0.001 a compared to constipated 
control, bCompared to 100,200 & 400mg/kg 
4.4.2 Gastrointestinal motility effect of crude extract in loperamide induced constipated mice 
As presented in Table 3 below the GI transit ratio of constipated control is decreased 
compared to normal control (p<0.01). The mean percentage of the GI transit ratio was 
increased in crude extract treated groups compared to constipated control at 200mg/kg 
(p<0.01) and 400mg/kg (p<0.001) doses of the plant extract. The highest dose (400mg/kg) 
also showed a significant difference relative to 100mg/kg (p<0.001). The standard drug 
produced significantly increased intestinal motility compared to constipated control 
(p<0.001), 100mg/kg treated (p<0.001) and 200mg/kg crude extract treated (p<0.01) groups. 
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Table 3 GI transit effect of crude extract of leaves of G. ferruginea in loperamide induced 
constipated mice 
Group Dose Total small 
intestine 
length (cm) 
Distance 
travelled by 
charcoal 
(cm) 
GI transit ratio (%) 
Constipated control 
(2% tween 80) 
10ml/kg 64.75±1.89 39.13±0.83 60.57±2.07 
Normal control (2% 
tween 80) 
10ml/kg 61.25±1.49 47.4±2.09 75.50±1.33a2 
 
Constipated + crude 
extract  
  
100mg/kg 65.40±1.78 42.60±2.32 65.01±2.27 
200mg/kg 59.75±2.32 45.00±2.17 75.24±1.16a2 
400mg/kg 58.80±2.15 47.20±2.10 80.74±3.1a3,b2 
Positive control 
(bisacodyl) 
0.25mg/kg 66.70±1.04 60.10±2.78 
a3,b2,c2 
89.97±3.07a3,b3,c2 
Result expressed as mean±SEM (n=5), 1P<0.05, 2p<0.01, 3p<0.001, a compared to constipated 
control, b compared to 100mg/kg, c compared to 200mg/kg 
4.4.3 Gastrointestinal secretion effect of crude extract on of normal mice 
As shown in Figure 3 below, the crude extract of G. ferruginea at 200mg/kg showed 
increased fluid accumulation compared to negative control and 100mg/kg (P<0.05). The 
highest (400mg/kg) dose and the standard drug (castor oil) showed highest accumulation of 
fluids compared to negative control as well as 100mg/kg crude extract treated groups 
(P<0.01).  
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Figure 3 GI Secretion effect of crude hydromethanolic extract of the leaves of G. ferruginea 
in normal mice 
Result expressed as mean±SEM, 1P<0.05, 2p<0.01 a, compared to the negative control, 
bcompared to 100mg/kg, MEGF-methanolic extract of G. ferruginea   
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5. DISCUSSION 
This study was done to evaluate the laxative activity of 80% methanol extract of Grewia 
ferruginea leaves against loperamide induced constipation in Swiss albino mice. The laxative 
activity of several traditionally used plants were approved scientifically through examining 
their activities in loperamide induced constipated and normal animal models. Measuring of 
stool parameters, intestinal transit ratio and intestinal fluid accumulation were the most 
frequent assessing methods (33, 78). These traditionally used plants improved defecation 
problems, intestinal transit ratio and enter-pooling activity in experimental animals (30, 34, 
39). Similarly, the crude extract of G. ferruginea showed good laxative activity in the present 
study.  
As it is depictive above (Table 2), mice treated with loperamide showed decrease frequency, 
weight of wet feces and fecal moisture content compared to un-constipated (normal control) 
group. These symptoms are manifestations of constipation (1, 2). It was indicated that the 
administration of loperamide 2-5mg/kg for three to seven days orally or subcutaneously can 
induce constipation effectively in rodents (34-36, 69, 70). Loperamide is good and preferred 
constipating agent because it acts peripherally with less CNS effect, little tolerance develops 
to constipating effect, more potent than morphine to inhibit motor activity through µ-
receptors and more effective than codeine (79).  
Administration of the crude extract of G. ferruginea increased weight of wet feces and 
percentage of fecal water content significantly in loperamide induced constipated mice 
compared to constipated control at all doses. Different studies revealed the presence of many 
phytochemical constituents like mucilages, propyl palmitate and short chain fatty acids 
(SCFA) in different Grewia species (42, 43). Plants with mucilage characteristics have water 
holding capacity and lubricating the bowel to facilitate the movement of stool (80). In 
addition, propyl palmate is emollient, moisturizer and anti-static agent (81). SCFAs stimulate 
longitudinal colonic smooth muscle contraction through the influx of extracellular calcium 
and facilitate the movement of GI contents (82). These constituents in different Grewia 
species may also present in G. ferruginea and could be responsible for its laxative activity. 
On the other hand, conventional laxative drugs, which increases the weight of wet feces and 
fecal fluid contents, commonly acted by absorbing water, increasing fecal mass, increasing 
expression of aquaporin, alter mucosal permeability and stimulate active anion secretion (22-
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26). From the results of the present study, the crude extract may have one of the above 
mentioned mechanisms of action. 
The standard drug (bisacodyl) showed a significant increase in frequency, fecal weight of 
wet and mean moisture content compared to constipated control. Studies showed that 
stimulant laxatives were used to oppose opioid induced constipation. They have 
physiological antagonist characteristics. Apart from other stimulant laxatives, which acts 
only on large bowel and metabolize to active component by colonic bacteria, that varies in 
different subjects, bisacodyl is hydrolyzed by intestinal enzymes and acts on both small and 
large intestines (83). Although the evidence is obscured, G. tiliafolia used to reverse opium 
toxicity in humans (42). These type of actions could be either via direct antagonize opioid 
action (opioid antagonist) or reversing physiological effects like stimulant laxatives (28, 83). 
These kind of nature in this species may also attributed to the action of G. ferruginea. 
In the present study even though there was no significant difference in the frequency of 
defecation, the crude extract still had benefit of treating constipation as it was found that at 
all doses, there was a statistically significant increase fecal mass and fecal water content 
compared to constipated control. Frequency increasing alone can’t determine the laxative 
activity of a given plant extract unless accompanied by increasing fecal mass and moisture. 
This activity can be best explained by the fact that some type of constipation characterized 
by hard and dry stool with a normal frequency of defecation or small and incomplete 
evacuation with frequent bowel movement. It also showed that constipation is more related 
to a condition of inability to evacuate stool completely and easily in every toilet rather 
counting number of bowel movements (3, 84). 
Based on the laxative effect of the crude extract obtained, the GI motility and intestinal fluid 
accumulation test were performed in order to predict the possible mechanism of action.  
The GI transit ratio was lower in constipated control group relative to normal control. This 
was due to the decreasing GI motility effect of loperamide (79). The GI motility effect 
increases with increasing dose. This action could be from the fact that the higher doses could 
contain many active constituents than the lower dose. The effect was comparable to the 
positive control bisacodyl. Bisacodyl induce irritation in the small and large bowel mucosal 
nerve ending to promote the accumulation of water and electrolytes and stimulate intestinal 
motility (15). Cholinergic agents and serotonin (5-HT4) receptor agonists also enhance 
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gastrointestinal motility in response to intra-luminal stimuli (29). Previous study on a crude 
alcoholic extract of G. asiatica fruits and leaves showed metoclopramide (known prokenetic 
agent) like activity to inhibit apomorphine induced emesis in dogs (49). This dopamine 
inhibiting characteristic of G. asiatica could share with G. ferruginea and accelerate gastric 
emptying. Another study on G. bicolor root extract showed serotonin like effect on rat uterus, 
rat fundus, rabbit jejunum and a transient serotonin like rise in cat blood pressure (52).  
Moreover, G. bicolor and G. ferruginea  both species traditionally used for laxative, 
deworming and retained placenta (51, 54). Therefore, G. ferruginea  may have similar active 
constituents and enhance GI motility from the rationale that plants in the same genus could 
have similar activity (85). 
The third model was done to investigate the small intestinal fluid accumulation effect of G. 
ferruginea  as evaluated by calculating the weight difference of the small intestine before 
and after removing the internal content (75). The crude extract of G. ferruginea increased 
intestinal fluid accumulation at middle and higher dose significantly compared to the 
negative control. The effect was comparable to the standard drug (castor oil). Castor oil 
contains triglyceride of ricinoleic acid that metabolized to glycerol and active chemical 
(ricinoleic acid) in the intestine (15) and increase intestinal fluid accumulation through 
different mechanisms such as inhibiting the enzyme Na+, K+ ATPase, irritating intestinal 
wall, stimulate cAMP and increasing prostaglandin release (24, 25). All these actions 
together increase overall secretion of water and electrolytes into the bowel. In addition to 
these, laxative agents that increased water and electrolyte secretion in the intestinal lumen 
through facilitating activation or expression of CFTR or aquaporin can accelerate intestinal 
fluid accumulation (23, 26). The positive effect of G. ferruginea on intestinal fluid 
accumulation could be one of the aforementioned mechanisms.  
Preliminary phytochemical screening of the crude extract of G. ferruginea revealed the 
presence of phenols, flavonoids, steroids, saponins and tannins. Preliminary phytochemical 
analysis of the different plant extracts containing secondary metabolites like flavonoids, 
saponins, tannins, sterols, reducing sugars and triterpenoids were reported to have stimulant, 
laxative and GI propulsive activity (38-40). Specifically,  olaxoside, a saponin isolated from 
the methanolic extract of different species of  Olax  genuses showed laxative activity in mice 
(86).  Saponin also have smooth muscle contraction effect (87). Some type of flavonoids like 
nargenins and apigenin also increase of Cl- secretion in colonic epithelia of loperamide 
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induced constipated animals and have a good laxative profile (88). Additionally, insoluble 
and poorly fermentable fibers, like, lignans increases stool bulkiness and GI transit (15). 
More interestingly, nargenins and lignin also found in grewia species of G. astiatica and G. 
bilamellata respectively (41). Even though the specific type of secondary metabolites and 
chemical constituents of crude extract of G. ferruginea is needs to be identified, the presence 
of similar preliminary phytochemicals to the above species may contribute to its anti-
constipation effect. 
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6. CONCLUSION 
The result of the present study indicated that 80% methanol extract of the leaves of G. 
ferruginea possessed significant laxative activity. It showed increasing of stool weight and 
fecal water content, promoting gastrointestinal motility and intestinal fluid accumulation in 
mice. Even the specific molecular mechanism should be studied in detail, from the present 
study it could be conclude that the general mechanism of actions could be either by 
increasing GI motility or secretion or both. So, the result corroborates the traditional claim 
of using G. ferruginea in the treatment of constipation.  
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7. RECOMMENDATIONS 
Based on the result of this study I recommend the following points: 
 Further fractionation studies should be conducted to identify and isolate active 
constituents responsible for laxative activity. 
 Sub-acute and chronic toxicity study should be performed to determine its long term 
safety profile 
 Electrolyte levels and histologic study should be performed to identify the change 
in electrolytes balance   
 The specific mechanisms of the active chemical component should be studied 
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9. ANNEX 
Preliminary phytochemical Screening Test 
Alkaloids (Mayer’s test) 
About one milliliter of extract was treated with 2-3 drops of Mayer’s reagent and observed 
for the formation of creamy or white  precipitate as a positive result (64). 
Glycosides (Keller-kilani test) 
Two milliliters of crude extract was mixed with 2ml of glacial acetic acid containing 1-2 
drops of 2% solution of FeCl3. Then the mixture poured into another test tube containing 
2ml of concentrated H2SO4. Development of a brown ring at the inter-phase indicate the 
presence of cardiac glycosides (65). 
Phenols 
The formation of deep blue or dark green when 3ml of the extract was treated with 5% ferric 
chloride solution showed the presence of phenol (64). 
Flavonoids 
About 2ml of dissolved crude extract was treated with 2-4 drops of 2% lead acetate solution. 
Formation of yellow or orange color indicates the presence of flavonoids (67). 
Steroids 
A few ml of crude extract was mixed with 2ml of chloroform and 2ml concentrated H2SO4. 
The formation of red color in the chloroform layer was taken as a positive result for steroids 
(65). 
Terpenoids  
About five milliliters of dissolved crude extract was mixed with 2ml of chloroform and 3 ml 
concentrated supheric acid. A reddish brown coloration of the interphase was indicative of 
terpenoids in the extract (67). 
Tannins  
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When 2ml of extract treated with few drops of 2% FeCl3 solutions and formation of green 
precipitate indicates the presence of tannins (65). 
Anthraqunones 
About 5g of crude extract dissolved in 10ml benzene and filtered. Five ml of 10% ammonia 
was added to the filtrate. Then the filtrate was shaken and observed the presence of violet 
color in the lower ammonia phase that showed the presence of anthraqunones (66). 
Saponins  
The crude extract was mixed with 5ml of distilled water in a test tube and it was shaked 
vigorously. The formation of stable foam (around 30min) was taken as an indication for the 
presence of saponins (65). 
 
